We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!
Episodes
Friday Jul 10, 2015
Friday Jul 10, 2015
The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM. The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.